Maxim Group Releases a Hold Rating on ContraVir Pharmaceuticals Inc

By Jason Carr

In a report released today, Jason McCarthy from Maxim Group assigned a Hold rating to ContraVir Pharmaceuticals Inc (NASDAQ: CTRV). The company’s shares opened today at $1.92, close to its 52-week low of $1.64.

McCarthy noted:

“Summary Contravir announced new preclinical data for cyclophilin inhibitor CRV431 in preclinical models of hepatocellular carcinoma (HCC) demonstrating reduced tumor nodules, including 25% of animals with no liver tumors at the end of the study. Why is this significant? CRV431 is being developed for HBV infection. Demonstration of efficacy (preclinical) in liver cancer, 80% of which is correlated to HBV antigens, suggests this compound could have potential as a cancer drug in addition to being developed as a component of an HBV regimen. CRV431 Data: The study data indicated that CRV431 reduced the number of tumor nodules by 44% and the overall tumor burden by 56% compared to the vehicle alone (p=0.02). At week 10 of the study, 25% of the treated mice were tumor-free while all of the mice treated with the vehicle had at least 5 tumors.”

According to, McCarthy is a 4-star analyst with an average return of 6.3% and a 45.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and Actinium Pharmaceuticals.

ContraVir Pharmaceuticals Inc has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.60 and a one-year low of $1.64. Currently, ContraVir Pharmaceuticals Inc has an average volume of 764.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. The company’s two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.